Quantcast

Latest fibrosis Stories

2014-09-16 20:27:17

-- Survey Data Requested by FDA for the September 26 Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis CHICAGO, Sept. 16, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced today that it has submitted survey data from more than 1,100 patients and families suffering from pulmonary fibrosis (PF) to the U.S. Food and Drug Administration (FDA) for the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis on...

2014-09-02 16:25:40

Mayor Rahm Emanuel declares September Global Pulmonary Fibrosis Awareness Month in Chicago--the Pulmonary Fibrosis Foundation sponsors events to enhance disease awareness and provides patient and caregiver feedback to the FDA CHICAGO, Sept. 2, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) launches a full month of events and initiatives for September's Global Pulmonary Fibrosis (PF) Awareness Month, starting with a proclamation by Chicago's mayor; surpassing a...

2014-08-14 16:27:01

New data will be reported to FDA at patient-focused drug development meeting on 9/26; insights will help future PFF programs and services CHICAGO, Aug. 14, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced that it has funded a survey designed to collect patient insights, which will help inform decision makers with a better understanding of pulmonary fibrosis (PF). The information collected will provide a better understanding of patients' and...

2014-08-05 08:34:38

MORRISTOWN, N.J., Aug. 5, 2014 /PRNewswire/ -- Moerae Matrix, Inc. announced today the initiation of a Phase 1 clinical trial of MMI-0100, a first-in-class inhibitor of MAPKAP Kinase 2 (MK2) being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases characterized by inflammation and fibrosis. The Phase 1 study is being conducted in the Netherlands and will evaluate the safety, tolerability and pharmacokinetics of ascending doses of MMI-0100 when given...

2014-07-23 16:27:13

Patients, caregivers and health care professionals share stories; offer awareness, hope and inspiration CHICAGO, July 23, 2014 /PRNewswire-USNewswire/ -- Twenty of the Pulmonary Fibrosis Foundation's advocates have come together to inaugurate PFF Ambassador program, a group of idiopathic pulmonary fibrosis (IPF) patients and caregivers who are committed to share personal stories of living with IPF as well as health care providers who deliver current disease education information to...

2014-07-21 20:22:22

Nintedanib and Pirfenidone Received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) - PFF Disease Education Webinars scheduled CHICAGO, July 21, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) is pleased to announce two upcoming webinars, one of which is related to the U.S. Food and Drug Administration (FDA) granting breakthrough therapy designation for two new investigational treatments for idiopathic pulmonary fibrosis (IPF)....

2014-07-16 08:27:08

MENLO PARK, Calif., July 16, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million. Including this recent $8 million investment, Virobay has raised an aggregate of $18 million in two tranches of the Series B financing. The first tranche...

2014-06-25 12:30:48

MENLO PARK, Calif., June 25, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a broad platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseases and fibrosis, today announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014. Mr. Welch has more than 20 years of experience in financial and operational management at life science and high technology firms....

2014-06-10 12:30:38

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Fibrosis - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/treatments/fibrosis_pipeline_review_h1_2013.html Fibrosis - Pipeline Review, H1 2014SummaryGlobal Markets Direct's, 'Fibrosis - Pipeline Review, H1 2014', provides an overview of the Fibrosis's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Fibrosis, complete...

2014-06-10 12:30:16

CHICAGO, June 10, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013. "Our partnership with Biogen Idec will further enhance the PFF Patient Registry, allowing us to investigate fundamentally important questions in...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related